91349-44-9Relevant academic research and scientific papers
AMINOIMIDAZOPYRIDINES AS KINASE INHIBITORS
-
Page/Page column 64, (2019/05/22)
Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
IMIDAZO-FUSED HETEROCYCLES AND USES THEREOF
-
Paragraph 0138; 0139, (2016/10/31)
Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using imidazole-fused heterocycle amines. Some of the disclosed embodiments include imizazo-fused
PYRAZOLE SUBSTITUTED IMIDAZOPYRAZINES AS CASEIN KINASE 1 D/E INHIBITORS
-
Page/Page column 151, (2014/07/08)
The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE
-
Page/Page column 18, (2011/02/18)
The present invention relates to modulators of IRAK kinase and provides compositions comprising such modulators, as well as methods therewith for treating conditions or diseases mediated by or associated with IRAK kinase.
FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE
-
Page/Page column 163, (2010/09/18)
The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.
Inhibitors of PI3 kinase
-
Page/Page column 19-20, (2009/07/10)
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.
FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS
-
Page/Page column 87, (2009/12/05)
The invention relates to compounds of formula (I), for the regulation of phosphoinositides 3-kinases activity and related diseases.
